Jason Haas's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 7,138 Common Stock done at an average price of $292.8 . Disclosure was reported to the exchange on Aug. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Sale of securities on an exchange or to another person at price $ 292.81 per share. | 12 Aug 2026 | 7,138 | 3,981 (0%) | 0% | 292.8 | 2,090,062 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.56 per share. | 12 Aug 2026 | 6,138 | 11,119 (0%) | 0% | 51.6 | 316,475 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 12 Aug 2026 | 6,138 | 0 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Sale of securities on an exchange or to another person at price $ 256.08 per share. | 12 Jun 2026 | 3,461 | 4,981 (0%) | 0% | 256.1 | 886,286 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.56 per share. | 12 Jun 2026 | 3,000 | 10,442 (0%) | 0% | 51.6 | 154,680 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Sale of securities on an exchange or to another person at price $ 255.01 per share. | 12 Jun 2026 | 3,000 | 8,442 (0%) | 0% | 255.0 | 765,034 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 12 Jun 2026 | 3,000 | 7,138 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.56 per share. | 12 Jun 2026 | 1,000 | 11,442 (0%) | 0% | 51.6 | 51,560 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 12 Jun 2026 | 1,000 | 6,138 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 05 Jun 2026 | 2,938 | 2,938 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2026 | 836 | 7,442 (0%) | 0% | 0 | Common Stock | |
| Odyssey Therapeutics Inc | Mr. Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 20.00 per share. | 08 May 2026 | 1,000 | 62,908 | - | 20 | 20,000 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 6,606 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.21 per share. | 18 Nov 2024 | 137,803 | 0 (0%) | 0% | 0.2 | 28,980 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 0 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 143,427 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 5,624 | 137,803 (0%) | 0% | 2.1 | 11,754 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.68 per share. | 10 Sep 2024 | 45,344 | 124,552 (0%) | 0% | 1.7 | 76,006 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.55 per share. | 10 Sep 2024 | 35,363 | 59,915 (0%) | 0% | 1.5 | 54,788 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.58 per share. | 10 Sep 2024 | 19,293 | 79,208 (0%) | 0% | 1.6 | 30,446 | Common Stock |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 5,397 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 29,284 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,732 | 24,552 (0%) | 0% | 5.1 | 24,228 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 15,951 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 4,145 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 1,377 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 49,750 | 49,750 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 37,750 | 37,750 | - | - | Restricted Stock Units | |
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | 29 Jun 2022 | 5,907 | 5,907 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Ligand Pharma Inc (Class B) | Mr. Jason Haas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 1,750 | 1,750 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc | Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units |